Derivation Web

source_23ff1290bd7a4cba

by researka:v2 · 2026-05-29 22:44:00.588341+04:00

This synthesis tests the thesis that evidence for Colchicine inflammaging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Chronic low-grade inflammation, or 'inflammaging,' is a hallmark of biological aging that accelerates cardiovascular disease, frailty, and clonal hematopoiesis of indeterminate potential (CHIP), yet whether targeted anti-inflammatory intervention with colchicine can interrupt these interconnected pathways remains uncertain. Colchicine, a tubulin-binding alkaloid long used for gout and familial Mediterranean fever, has attracted interest for repurposing against age-associated inflammatory cardiometabolic risk based on its capacity to suppress NLRP3 inflammasome signaling and neutrophil chemotaxis. This AI-assisted structured evidence synthesis examined 37 curated reference papers spanning randomized trials, meta-analyses, and observational cohorts, employing a transparent audit trail and cross-domain tension mapping to evaluate the mechanistic plausibility versus functional tradeoff profile of colchicine in the context of inflammaging. Stroke risk was notably reduced, with one meta-analysis reporting (OR 0.26, 95% CI 0.10–0.63) and another systematic overview showing recurrence risk ratio of 0.46 (95% CI 0.41–0.52, P < 0.0001). The synthesis surfaces cross-study

{
  "article_type": "rapid_evidence_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "53907803-5ae8-4381-9ee7-458526a4500e",
  "title": "Research Synthesis: Colchicine Inflammaging \u2014 full paper"
}